Bioventix (BVXP) AI Stock Analysis

• Market Cap: £74.45M
• Dividend Yield: 8.33%
• Average Volume (3M): 7.85K
• Price to Earnings (P/E): 18.9
• Beta (1Y): 0.36
• Revenue Growth: -3.61%
• EPS Growth: -6.35%
• Country: UK
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.72
• Shares Outstanding: 5,224,860
• 10 Day Avg. Volume: 9,152
• 30 Day Avg. Volume: 7,851
• PEG Ratio: -2.93
• Price to Book (P/B): 12.43
• Price to Sales (P/S): 10.95
• P/FCF Ratio: 20.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.36
• Revenue Forecast (FY): £12.50M

• Rating: 75 Outperform
• Price Target: 1,603.00 p ▼(-10.94% Downside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).

Positive Factors

Exceptional profitability margins

Bioventix’s sustained net margins near 58–70% reflect durable pricing power and low incremental costs for antibody reagents. Persistently elite margins support long-term cash generation, enable reinvestment in R&D and product support, and provide resilience if volumes fluctuate.

High-quality cash conversion

FCF that closely tracks net income indicates profits convert reliably to cash, enabling consistent funding of operations, dividends, and selective reinvestment. Strong cash conversion reduces refinancing risk and supports capital allocation through multi-year cycles.

Sticky royalty-based business model

Bioventix’s model—design-in of proprietary antibodies and ongoing royalties—is structurally durable: validated reagents embedded in regulated assays generate recurring revenues over many years, creating long-lived high-margin income once customers adopt the reagent.

Negative Factors

Recent revenue and cashflow slowdown

A measurable revenue and FCF decline in 2025 versus 2024 signals weakening operating momentum. Given Bioventix’s dependence on design-ins and customer assay volumes, a multi-quarter slowdown can materially compress royalty growth and delay the conversion of R&D efforts into recurring sales.

Market/customer pressures (China exposure)

Documented pressure in China and other market challenges represent structural demand risk for end-market assay volumes. Geographic or customer concentration can reduce durable royalty receipts and magnify downside if key customers or regions face regulatory, reimbursement, or demand headwinds.

Small balance sheet and limited scale

A shrinking equity/asset base plus a very small workforce (17 employees) constrains the firm’s ability to scale multiple design-ins simultaneously, absorb supply disruptions, or invest quickly to capture new opportunities, increasing sensitivity to single-customer or program setbacks.

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.

How the Company Makes Money

Bioventix primarily makes money by licensing and supplying proprietary monoclonal antibody reagents to in-vitro diagnostics (IVD) and immunoassay platform manufacturers. Revenue is typically generated in two main ways: (1) upfront/initial payments tied to access to or adoption of Bioventix antibodies for a specific diagnostic assay or platform, and (2) ongoing royalty income that scales with the customer’s commercial sales volumes of diagnostic tests that incorporate Bioventix’s antibodies. In addition, the company can earn product sales revenue from the direct supply of antibody reagents to customers (often under long-term relationships where Bioventix provides consistent lots/quality over the life of an assay). Because diagnostic assays can remain on the market for many years, successful antibody placements can produce recurring, high-margin royalty streams as test volumes grow. A key factor in earnings is securing design-ins with large IVD companies—once an antibody is validated and embedded in a regulated assay, switching suppliers is difficult and costly, which can support durable revenue. Specific customer names, contract terms, and the split between royalties versus reagent sales are not available here and are therefore null.

Bioventix Financial Statement Overview

Summary

Financials are very strong: elite profitability and cash conversion, with a conservative balance sheet (zero debt). The main offset is a clear recent slowdown, with 2025 showing declines in revenue and free cash flow versus 2024.

Income Statement

Bioventix shows exceptionally strong profitability, with consistently very high gross and operating margins and net profit margins holding near ~58–70% across recent years. Revenue expanded steadily from 2020–2024, but the latest year (2025) shows a modest revenue decline (about -4%), alongside lower net income versus 2023–2024—suggesting growth momentum has softened even though underlying profitability remains elite.

Balance Sheet

The balance sheet is very conservative: total debt is consistently zero and the company is funded primarily by equity. Returns on equity are extremely high (roughly mid-50% to ~70%), reflecting strong earnings power relative to the equity base. A watch-out is that equity and total assets have drifted down in the most recent year (2025 vs. 2024), which could limit balance sheet expansion if the softer top-line trend persists.

Cash Flow

Cash generation is strong and high quality: free cash flow closely tracks net income (near ~1.0 in recent years), indicating profits convert well into cash. Cash flow comfortably covers reported earnings, and free cash flow has generally grown over time, but it declined in 2025 (about -9%) after a strong 2024—mirroring the recent slowdown in revenue and earnings.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	13.12M	13.61M	12.82M	11.72M	10.93M
Gross Profit	11.92M	12.68M	11.86M	10.87M	9.98M
EBITDA	10.17M	10.74M	10.20M	9.42M	8.22M
Net Income	7.58M	8.10M	8.37M	7.67M	6.73M
Balance Sheet
Total Assets	12.86M	13.73M	13.28M	13.12M	12.91M
Cash, Cash Equivalents and Short-Term Investments	5.08M	6.00M	5.72M	6.13M	6.49M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.31M	1.73M	1.22M	1.30M	1.09M
Stockholders Equity	11.55M	12.00M	12.06M	11.82M	11.82M
Cash Flow
Free Cash Flow	7.01M	8.33M	7.89M	7.55M	6.11M
Operating Cash Flow	7.03M	8.34M	7.90M	7.56M	6.37M
Investing Cash Flow	173.16K	186.06K	90.51K	-11.76K	-259.83K
Financing Cash Flow	-8.12M	-8.25M	-8.30M	-7.92M	-7.69M

Bioventix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1800.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Negative. The current price of 1800 is above the 20-day moving average (MA) of 1567.50, above the 50-day MA of 1703.80, and below the 200-day MA of 2150.85, indicating a bearish trend. The MACD of -68.16 indicates Positive momentum. The RSI at 28.35 is Positive, neither overbought nor oversold. The STOCH value of 24.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BVXP.

Bioventix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£74.45M	18.93	66.44%	8.33%	-3.61%	-6.35%
APTA	52 Neutral	£22.25M	-3.03	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OBD	45 Neutral	£10.51M	-0.25	-316.67%	―	72.17%	79.03%
FAB	44 Neutral	£15.63M	-9.67	-210.32%	―	-11.43%	23.40%
AVCT	42 Neutral	£310.56M	-1.74	-361.23%	―	―	―
4BB	41 Neutral	£80.06M	-4.89	-63.53%	―	198.49%	-26.66%

Bioventix Corporate Events

Bioventix strengthens board with appointment of diagnostics veteran Chris Yates

Bioventix plc, the AIM-listed UK antibody developer and supplier, focuses on high-affinity monoclonal antibodies for clinical diagnostics and provides a broad portfolio of sheep-derived reagents to major multinational diagnostics firms. Its products are used in automated immunoassays for blood testing across a range of diseases and conditions, underpinning the company’s niche but globally integrated market position.

The company has appointed Chris Yates as an independent non-executive director, effective 1 March 2026, bringing over two decades of board-level experience in listed life sciences and diagnostics businesses. His track record at Abingdon Health and other AIM-listed diagnostics firms is expected to bolster Bioventix’s governance, commercial insight and strategic oversight as it continues to serve leading clinical diagnostics customers worldwide.

The most recent analyst rating on (GB:BVXP) stock is a Buy with a £1856.00 price target. To see the full list of analyst forecasts on Bioventix stock, see the GB:BVXP Stock Forecast page.